- kalina
- 17 Sep, 2002
- New York City
Important symposiums and regulatory reviews of drugs this September are likely to spark investor interest in biotech stocks and prompt a rally in case of positive developments.
- vicky
- 16 Sep, 2002
- New York City
In the current depressed market scenario, investors can easily avoid risk by putting money in the bank - but diversified financial stocks appear to be a good, flexible alternative
- iliana
- 12 Sep, 2002
- New York City
Supported by future growth potential and its current trimmed, attractive valuations, the stock of teen apparel retailer, Wet Seal, seems to be in fine shape to woo investors
- kalina
- 06 Sep, 2002
- New York City
Low valuations of industry top dogs and demographic changes in U.S. society offer good opportunities to investors seeking long-term gains. Find out which companies have real value.
- vanya
- 04 Sep, 2002
- New York City
A shaky market scenario has forced investors to diversify their portfolios and seek refuge in real estate, particularly REITs, - due to their relative stability and high yields.
- iliana
- 30 Aug, 2002
- New York City
For 16 straight years Harley-Davidson has given both investors and customers the same service - a smooth ride. But with stiff competition and aging riders the ride may turn bumpy.
- kalina
- 22 Aug, 2002
- New York City
NPS Pharmaceuticals has been showing strength amidst the market uncertainty and is likely to perform even better as long as investor sentiment remains positive.
- vanya
- 21 Aug, 2002
- New York City
Sometimes, something small draws big bets. MEMS is one such example - it has lured scores of VCs and players, big and small. Will the fledgling technology deliver on its promise?
- iliana
- 14 Aug, 2002
- New York City
Riding high in the robust housing market, Williams-Sonoma has consistently reported strong results. And though its price has soared, the stock is still a worthy long-term holding.
- kalina
- 13 Aug, 2002
- New York City
The increasing pressure on biotech companies to get new drugs to the market has triggered a new wave of merger and acquisition activity in the sector.
- vanya
- 09 Aug, 2002
- New York City
In contrast to the gloom surrounding public biotech players, VCs have pushed life sciences into the mainstream, pouring funds into biotech, medical devices and healthcare start-ups
- vicky
- 04 Aug, 2002
- New York City
In the case of wireless handset makers, depressed stock prices and the recent Wall Street rebound do not represent a buying opportunity - barring a couple of exceptions.
- iliana
- 01 Aug, 2002
- New York City
Though short-term sand traps lurk in the golf arena, Callaway's innovative products and cash-generating business offer good chances for investors to emerge as long-term winners
- kalina
- 01 Aug, 2002
- New York City
Despite the uncertainty over the timeline for FluMist's approval by the FDA, MedImmune may still launch the vaccine during the 2002/2003 flu season and cheer investors.